The necessary of heparin bridging therapy for the patients taking warfarin or Indirect and Direct Factor Xa Inhibitors undergoing colonic endoscopic mucosal resection.

The necessary of heparin bridging therapy for the patients taking warfarin or Indirect and Direct Factor Xa Inhibitors undergoing colonic endoscopic mucosal resection. - Safety of colonic endoscopic mucosal resection in patients taking anticoagulants.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023279

Enrollment

Registered

2016-07-21

Start date

2014-08-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon polyps

Interventions

Continuing warfarin or indirect and direct factor Xa inhibitors during endoscopic colonic polypectomy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients taking warfarin or indirect and direct factor Xa inhibitors with planning of endoscopic colonic polypectomy.

Exclusion criteria

Exclusion criteria: Number; more than 4 polyps Size; more than 10mm Patients; post heart mechanical valve replacement

Design outcomes

Primary

Measure	Time frame
The bleeding rate of post-endoscopic mucosal resection associated without cessation of indirect and direct factor Xa inhibitors.	—

Secondary

Measure	Time frame
The difference in bleeding rate of post-endoscopic polypectomy without cessation of anticoagulant agents compared with the previous rate of heparin bridge theraphy.	—

Countries

Japan

Contacts

Public ContactMinoru Fujita

Kawasaki Medical School Gastroenterology

minorufu@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026